# The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

> **NCT02484924** · — · COMPLETED · sponsor: **Liverpool University Hospitals NHS Foundation Trust** · enrollment: 5225 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Bleeding
- Novel Anti-platelets
- Ticagrelor
- Clopidogrel

## Interventions

- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT02484924
- **Lead sponsor:** Liverpool University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 5225 (ACTUAL)
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484924, "The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02484924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*